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Abstract
Introduction—Hemophilic siblings provide a unique population to explore the natural history of
chronic hepatitis C.
Methods—From 3,993 hemophilic patients with hepatitis C, 257 sibling pairs, in which both
members had evidence of hepatitis C infection, were studied to evaluate the genetic contribution to
spontaneous and treatment-induced clearance of hepatitis C infection and the progression of liver
disease. Familial aggregation was assessed by comparing observed probabilities of concordance
for these disease characteristics within sibling pairs to those expected for randomly paired
hemophilic subjects. Additional measures of familial aggregation, heritability and sibling relative
risk, were also calculated.
Results—Among HIV-negative subjects, concordance for spontaneous viral clearance was two-
fold higher in siblings compared to randomly paired subjects (8.8% vs 4.3%, p=0.04). Similarly,
the concordance rate for treatment-related viral clearance was over twice that among sibling pairs
than among randomly paired hemophiliacs (31.3% vs 13.3%, p=ns). Heritability estimates for
spontaneous and treatment-induced viral clearance were 0.24 ± 0.14 (p=0.04) and 0.43 ± 0.42
(p=0.10), respectively. The sibling relative risks for these respective characteristics were 1.6 and
1.7. Concordance for advanced liver disease was higher among siblings, but did not reach
statistical significance (4.0% vs 2.3%, p=ns). The heritability estimate was 0.29 ± 0.13 (p=0.02).
Conclusions—Concordance rates and heritability estimates for spontaneous and treatment-
related viral clearance indicate that genetic factors have a modest influence on the outcome of
hepatitis C, although shared environmental factors cannot be excluded. Investigations to map
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candidate disease-susceptibility genes associated with these characteristics must be approached
with caution.
Introduction
Hepatitis C virus (HCV) is unique among hepatotropic viruses for its propensity to cause
chronic infection and for the variable outcome of the disease. Population-based studies in
the United States indicate that approximately 75% of patients remain chronically infected
with hepatitis C (1). In contrast, up to 50% of patients have been reported to spontaneously
resolve hepatitis C infection when exposure occurred in children undergoing cardiac surgery
or cancer chemotherapy, in young women after a common-source outbreak of contaminated
anti-D immunoglobulin, or in healthcare workers after needlestick exposures (2-4).
The clinical spectrum of hepatitis C is also variable, ranging from asymptomatic, mild
infection to cirrhosis, portal hypertension and liver failure (5). Attempts to define the natural
history of hepatitis C have yielded conflicting results and indicate that the outcome is neither
uniformly fatal nor predictable. Fewer than 10% of European women infected with hepatitis
C from anti-D immunoglobulin, progressed to cirrhosis, and the majority had only mild
chronic hepatitis, after two decades of observation (2, 4, 6). Similarly, patients with hepatitis
C viremia may have persistently normal ALT activities during prolonged monitoring with
minimal histologic changes (7, 8). In an early study of transfusion associated non-A, non-B
hepatitis, there was a small but significant increase of liver related mortality in hepatitis
patients over an 18-year follow-up from the time of transfusion (9). In contrast, patients with
transfusion associated hepatitis C followed at a tertiary referral center had a high incidence
of cirrhosis and death from liver failure or hepatocellular carcinoma, although these results
were undoubtedly biased by the nature of the referral population. Nevertheless, end-stage
liver disease due to hepatitis C is the most common indication for liver transplantation in the
United States (10, 11).
The factors that contribute to the varied clinical course of this disease are largely unknown.
Epidemiologic studies have suggested that the likelihood of spontaneous viral clearance is
associated with age at infection, gender, race, and severe acute icteric illness (12-15).
Alcohol consumption greater than 50 grams per day, older age at acquisition, male gender,
and co-infection with human immunodeficiency virus (HIV) were independent risk factors
associated with more rapid progression of fibrosis in patients with hepatitis C (13, 16).
Interestingly, viral factors, such as hepatitis C genotype and level of HCV RNA have not
been consistently implicated as factors associated with viral clearance nor with increased
fibrosis (17-19).
While this information has been valuable in helping clinicians to stratify the global risk of
chronic infection and disease progression for their patients, these epidemiologic factors are
unlikely to be solely responsible for clinical outcomes. Complex interactions must exist with
other host factors, including the immune response and host genetic variables that mediate
expression of antiviral response, but are far more difficult to study.
Increasing emphasis is being placed on the investigation of host genetic factors that may be
associated with the natural history, clinical manifestations, or response to therapy of chronic
hepatitis C and other liver diseases. Recent data suggests that polymorphisms of genes
associated with hepatic fibrogenesis, oxidant stress, immune response, or antiviral defense
mechanisms may influence the course of chronic liver disease (20-26). However, these
studies are often limited by a small sample size from tertiary centers that may not represent
individuals spanning the entire spectrum of disease (27). In addition, these studies have
focused on only single genes, some with polymorphisms of uncertain functional
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significance, and usually did not attempt to evaluate gene-environment interactions that
could affect interpretation of the results (27). Furthermore reporting bias for nominally
significant results, inadequate correction for multiple comparisons (28) or realistic
assessment of the prior probability for association(29) and failure to consider population
stratification (30-32) may make the available association analysis literature suspect.
The aim of the present study was to assess the relative contributions of genetic factors in the
evolution of hepatitis C disease in a unique group of hemophilic siblings. Individuals with
inherited coagulation disorders (hemophilia and von Willebrand’s disease, referred to herein
as hemophilia) who received unsterilized blood products have a prevalence of hepatitis C
infection (70-90%) that is unsurpassed by any other defined risk group (14, 18, 33-35).
Hemophilic siblings are an attractive population to study in relation to the natural history of
hepatitis C because: 1) They are almost exclusively males; 2) Siblings are relatively close in
age and duration of follow-up; 3) The mode of HCV acquisition is identical; 4) The date of
acquisition can be estimated based upon their factor replacement history; 5) The age of HCV
acquisition is similar; and 6) Siblings share varying degrees of genetic material. The
following analyses have important implications for mapping candidate disease modifying




Subjects for this study were derived from participants in two large, consecutive studies of
patients with hemophilia that were exposed to unsterilized blood products. The first
Multicenter Hemophilia Cohort Study (MHCS-I) (36, 37), funded by the National Cancer
Institute, was initiated in 1983 and maintained follow-up for enrollees through 1999.
MHCS-I included all hemophiliacs registered at 17 participating treatment centers in five
countries. The second Multicenter Hemophilia Cohort Study (MHCS-II), initiated in 2001,
included hemophiliacs from 54 participating treatment centers (13 centers from MHCS-I) in
eight countries (38). Eligibility criteria included at least 13 years of age at the time of
enrollment and previously confirmed infection with HCV.
From the combined MHCS-I and II HCV-infected cohorts (n=3,993), 257 families that had
two or more infected whole siblings, where both members were positive for anti-HCV, were
identified and served as the initial study group of interest. In 24 families with more than two
eligible siblings, two were randomly selected to form a pair for the subsequent analyses.
Each sibling pair was assigned a unique numeric identifier. All subjects (or their legal
guardians) provided written informed consent prior to blood collection and examination
under a protocol approved by all participating institutions.
Definitions
Date of infection—The date of infection was estimated for all subjects based on their
hemophilia type and severity and factor replacement histories, as has been previously
described (15). For the current study, the date of infection was imputed as the midpoint
between the exposure interval with the first use of factor concentrate defining the upper limit
(MATLAB, MathWorks, Natick, MA). Dates of infection for individuals with missing factor
replacement histories were estimated as the median date of infection for the group of
individuals with known histories, born within 3 years, and having the same hemophilia
severity.
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HCV Clearance—HCV clearance was defined as undetectable HCV RNA levels (bDNA
(Bayer), Amplicor (Roche) and/or TaqMan PCR) in the most recent sample tested. Subjects
meeting this definition were further classified as spontaneously clearing their infection if
they had never been treated with interferon-based therapy. HCV RNA clearance was
considered to be treatment-induced for those subjects who had received any interferon-based
therapy either alone or in combination with ribavirin.
Advanced liver disease: Participants were considered to have advanced liver disease
(ADV) if they met at least one of the following criteria:
1. Liver biopsy demonstrating stage III or stage IV fibrosis or the presence of
cirrhosis as a descriptor
2. The presence of ascites, or esophageal varices.
3. Liver disease as a cause of death on the death certificate
4. Primary liver cancer
5. The presence of at least 2 of the following conditions: hepatic encephalopathy,
albumin <= 3.0 g/dl, or prolonged prothrombin time > 15 seconds
6. One of the conditions in #5 above plus hyperbilirubinemia ≥ 2.5 mg/dl, or platelet
count ≤ 120,000 cells/mm3; or
7. Last two platelet counts < 100,000 cells/mm3
The date of ADV was considered to be the date of the earliest diagnosed event in categories
1-5 above, and the date of the second abnormal laboratory result in categories 6-7
Statistical analysis
The expected and unadjusted probability of two randomly selected individuals having a
concordant diagnosis of spontaneous or treatment-induced HCV clearance or ADV was
calculated as the square of the population frequency for those at risk for the two events.
Similarly, the probabilities of two individuals being discordant for disease or concordant for
the absence of disease were also calculated. The concordance and discordance frequencies
of the random pairs were compared with those of the sibling pairs using the Breslow-Day
test for homogeneity comparing two odds ratios. Because of its strong and potentially
modifying effect, analyses were stratified by HIV status.
The individual probabilities (cumulative hazards) of being diagnosed with advanced liver
disease after HCV seroconversion was determined for each sibling from proportional
hazards models of all subjects with non-missing data. Subjects that had spontaneously
cleared their HCV infections were not considered at risk for HCV-related liver disease and
excluded from this analysis. Cumulative hazards for 2238 subjects, including 125 complete
sibling pairs, were adjusted for age at HCV infection, birth year, HIV status, and HBV
chronicity by including these variables in the models.
The cumulative hazard for each sibling was subtracted from his disease indicator flag (1 for
ADV, 0 for no ADV), resulting in a residual risk that represented the observed minus the
expected probability for advanced liver disease (39).
Concordance of the residual risks between siblings in the same family was evaluated by
analysis of variance with the residual risk as the dependent variable and the pair number as
the independent variable. The intraclass correlation coefficient (ICC), or the proportion of
variation that occurred among the pairs, was calculated from the sum of the mean squares
within and between sibling pairs (39). If genetics were the sole factor associated with HCV
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clearance or disease progression and all siblings shared the expected gene, the expected ICC
= 1. The null hypothesis of ICC=0 was tested using the F statistic.
Measures of familial aggregation
Heritability (h2) of a trait is the proportion of total variance of a phenotype that is genetic
(40). It is customary to use twin data to estimate the proportion of phenotypic variance that
is due to genetic, shared and nonshared environmental factors. In most twin analysis there is
assumed to be an additive mode of inheritance. Family studies with a variety of relationship
types are used to determine the most probable mode of inheritance. In this data set only
sibling data are available such that it is impossible to have insight into the mode of
inheritance or to disentangle shared environmental and genetic contributions to
susceptibility. In these analyses we assume that there are no shared environmental effects.
Thus, h2 represent an upper limit of the genetic contribution.
h2 estimates were calculated for spontaneous and treatment-induced viral clearance and for
the presence of advanced liver disease using the SOLAR, version 2.1.4 (41). The phenotype
for an individual is assumed to be equal to the sum of the population mean, products of
covariate values for the individual and covariate regression coefficients, and the deviation
from the mean due to genetic and residual effects (usually called the environmental effects).
It is assumed that the deviations from the mean due to genetic and environmental effects are
not correlated and are normally distributed with mean 0 and variance of σ2g and σ2e.
Assuming the simplest model, it follows that covariance for relative pairs is equal to 2 times
the kinship coefficient times σ2g plus σ2e and the variance due to covariates. h2 is defined as
σ2g /(σ2g + σ2e). In this model the estimates of h2 can be increased when covariance for
relative pairs due to shared environmental effects are correlated with he kinship coefficient.
Sibling relative risk
The sibling relative risk, λs, is another measure of familial aggregation that is commonly
used to assess the feasibility of genetics studies (42). λs, (the risk of a sibling of an affected
individual divided by the population risk) is commonly used as an upper bound for the
genotypic relative risk which together with disease associated allele frequency determines
the sample size required to detect a significant association. We assumed that the risk of an
affected individual sibling is equal to the number of concordant affected sibling pairs
divided by the number of concordant affected sibling pairs plus half of the discordant sib
pairs. The population risk was estimated from population of sporadic individuals. Most traits
that are considered tractable for genetic analysis have λs greater than 2.3 and preferably
greater than 10.
Results
The demographic and descriptive data of the hemophilic population and the sibling subset is
provided in table 1. Three-quarters of the total study population had hemophilia A and two-
thirds were characterized as severe hemophilia. Forty-six percent were infected with HIV.
These characteristics were more frequent in the subset of 514 siblings (p≤0.04) which was
due to targeted recruitment of HIV-infected siblings for MHCS-1 (39). The median age at
the time of HCV infection for the total population and the subgroup of siblings was 7.5 years
and the median duration of HCV infection was 25 years. The prevalence of chronic hepatitis
B carriers (HBsAg) did not differ significantly (6.6% vs 7.4%, respectively). More than half
of the hemophilic subjects did not drink any alcohol and an additional 38% drank only 1
drink per week. Thus, 89% of hemophilics drank little or no alcohol, which was similar
between the total hemophilic population and siblings.
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Familial aggregation for spontaneous HCV clearance in the sibling pairs
Spontaneous clearance of HCV infection occurred in 562 (16.4%) hemophiliacs. Of these,
365 were HIV-negative and 197 HIV-positive. Among siblings, spontaneous clearance was
seen in 15.6% (p=ns). The probability of two randomly paired individuals having
spontaneously cleared their infection was 2.7% in the total population at risk. In comparison,
there were 9 sibling pairs (4.0%) concordant for spontaneous clearance from the 228 sibling
pairs at risk (p= 0.07) (Table 2). Among the HIV-negative subjects, the expected
concordance for spontaneous clearance between two randomly paired individuals was 4.3%.
Of the 80 HIV negative sibling pairs, 7 were concordant for spontaneous clearance (8.8%, p
= 0.04) (Table 2).
h2 for spontaneous viral clearance was 0.25 ± 0.14 (p=0.04 that h2 significantly different
than zero; see table 3). The sibling relative risk, λs, was estimated to be 1.6.
Familial aggregation for treatment-related HCV clearance in the sibling pairs
Six-hundred sixty-four (17.6%) hemophilic subjects had received treatment for chronic
hepatitis C with an interferon-based regimen. Twenty-seven percent of these were treated
with interferon monotherapy while 73% had received combination therapy with interferon or
peginterferon and ribavirin. Among the treated subjects, 36% demonstrated sustained
virological response. Therefore, the probability for two randomly paired individuals having
virological concordance for sustained virological response was 13.3%. Remarkably, among
16 sibling pairs, both of whom had received therapy for chronic hepatitis C, five pairs
(31.3%) were concordant for sustained viral clearance. This did not reach statistical
significance (Table 2). In three additional pairs, neither cleared HCV RNA, while in 8 pairs
one sib cleared while the other remained infected.
h2for treatment-related viral clearance was 0.43 ± 0.42 (p=0.10 for h2 being different than 0)
while the sibling relative risk was 1.7 (Table 3). These measures of familial aggregation are
imprecise because of the sample size.
Familial aggregation for liver disease in the sibling pairs
In a subset 2238 subjects with persistent hepatitis C and complete data, advanced liver
disease developed in 15.1%. The clinical characteristics defining advanced liver disease are
shown in table 4. The probability of two randomly paired individuals having ADV was
2.3%. In comparison, there were 5 sibling pairs (4%) concordant for ADV out of the 125
total pairs at risk (p = ns), suggesting a weak familial component to advanced liver disease.
From these data, heritability for advanced liver disease was 0.29 ± 0.13 (p=0.02 for h2 being
different than 0) while the sibling relative risk was estimated to be 2.1 (Table 3).
We next examined this familial association by analyzing the time from HCV infection to
ADV in a proportional hazards model that included age at HCV infection (p<.0001), HIV
status (p<.0001), HBsAg carriage (p=.05), and birth year (p<.0001). Alcohol usage was not
a significant predictor of ADV, and therefore, not included in the model. After adjusting for
other factors that were significantly associated with progression to ADV, there was no
concordance for disease within the sibling pairs (ICC=0.0). When we included only those
1764 subjects that had been infected with HCV for at least 20 years, the ICC in the 96
sibling pairs was 0.09.
Discussion
The present study evaluated a unique cohort of hemophilic siblings to ascertain the relative
influence of familial relationship on HCV viral clearance and on progression to advanced
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liver disease. Several novel features distinguish this study from others that have tried to
address questions regarding the natural history of hepatitis C infection. The relatedness of
the sibling pairs, the ability to reliably estimate the duration of HCV infection, and the
homogeneity of the cohort related to gender, age at infection, alcohol intake, and mode of
acquisition provide a rare opportunity to evaluate the influence of host genetics on hepatitis
C infection.
Spontaneous resolution of hepatitis C infection occurred in approximately 17% of all
subjects in this study, with a substantially lower rate of viral clearance among those co-
infected with HIV. These rates of viral clearance are consistent with other reports in non-
hemophilic populations (1), although somewhat less than reported in children and young
women infected through contaminated blood products (4, 43). In the hemophilia cohort,
repeatedly exposed to unsterilized blood products, it is possible that single episodes of
spontaneous viral clearance were overshadowed by reinfection during subsequent exposures,
as has been demonstrated in thalassemic patients who developed repeated episodes of acute
hepatitis C following multiple exposures (44). Thus, the hemophilic subjects in the present
study represent those with durable viral clearance suggesting a robust antiviral response, the
nature of which is worthy of further investigation.
The present study found that concordance for spontaneous viral clearance was significantly
greater among sibling pairs than among randomly assigned pairs of hemophilics. This
concordance in viral clearance supports the hypothesis that host antiviral response is
influenced by genetic factors shared within the sibships. This finding is consistent with
studies that have found an association between a variety of single gene polymorphisms
involved in the immune response and HCV viral clearance (45-48). Thus, genes encoding an
inhibitory natural killer (NK) cell receptor and IL-10 have been associated with viral
clearance while polymorphisms of HLA-Cw*04 and tumor necrosis factorα have been
implicated in HCV viral persistence (45-48).
Remarkably, we have also demonstrated that the observed concordance within sibships for
viral clearance as a result of antiviral therapy is over twice what would be expected from
randomly paired, unrelated subjects with hemophilia and hepatitis C. However, due to the
small sample size of treated sib pairs, this did not reach statistical significance. Nevertheless,
this information provides additional support for a relationship between host genetics and
HCV viral clearance and is consistent with several recent reports that evaluated gene
expression and gene polymorphisms in individuals with and without sustained virological
response to interferon-based regimens (49-54). Using microarrays in hepatic tissue, Chen
and colleagues identified a number of interferon-sensitive genes that correlated with
response to antiviral therapy (50). Similarly, among black and white patients with chronic
hepatitis C treated with interferon, different patterns of expression of interferon-stimulated
genes, such as 2,5-OAS, MxA, and PKR, were identified between individuals of African and
European ancestry, suggesting potential mechanisms for diminished response to antiviral
therapy seen in African American patients (55). The vast majority of subjects in the present
study were of European ancestry.
Approximately 15% of hemophilics infected with hepatitis C developed advanced liver
disease over a prolonged period of observation, a prevalence rate that is less than those
reported in studies of non-hemophilics. This relatively low rate of disease progression is
unexpected, particularly since many subjects were co-infected with HIV, a combination that
has been repeatedly demonstrated to increase the likelihood of disease progression. Goedert
et al (14) analyzed the incidence of end-stage liver disease in the first Multicenter
Hemophilia Cohort Study and found a similar rate of end-stage liver disease (14%) for those
co-infected with HIV but only 2.6% for those without HIV infection.
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The criteria to define advanced liver disease in the present study utilized stringent clinical
and/or laboratory endpoints. Although liver biopsies can be safely performed with
appropriate precautions in individuals with inherited disorders of coagulation (56), liver
biopsies were infrequently performed. Therefore, it is possible that the extent of cirrhosis, in
those without clinical or laboratory evidence of advanced disease, was underestimated.
Nevertheless, we do not expect that this was a significant confounder in our analyses,
particularly because the same clinical criteria were applied uniformly across the sib and non-
sib groups. This cohort also had a low frequency of alcohol ingestion, another co-factor
believed to accelerate HCV disease progression. The vast majority of participants (88%)
reported drinking one or less than one alcoholic beverage per day.
It is assumed that complex traits, such as HCV viral clearance and development of cirrhosis,
occur as the result of the interaction between genetic and environmental factors. Indeed, a
recent study that evaluated non-genetic factors in a cohort of hemophilic subjects has
suggested that coinfection with hepatitis B, recent year at infection, and younger age at
infection were associated with spontaneous viral clearance (15). In that study, no attempt
was made to evaluate potential genetic factors. The present study, however, utilized an
expanded cohort of these hemophilic subjects and specifically sought to evaluate the genetic
influence on viral clearance and disease progression by exploring these phenotypes within
sibling pairs. The results of these two studies, therefore, are complementary. The current
results, in aggregate, indicate that these outcomes (viral clearance and disease progression)
are also influenced by genetics, although to a modest degree. Heritability estimates,
providing a measure of the proportion of variance of a phenotype that could be attributed to
genetics, and the sibling relative risk, a measure of familial aggregation of a phenotype, are
in agreement with the concordance data. The entanglement of genetic and shared
environmental effects confound these measures of familial aggregation. By studying
siblings, we attempted to minimize the impact of disparate environmental factors, such as
age and duration of infection, gender, and mode of acquisition, that could influence the
phenotypes of viral clearance and progression of liver disease. Some portion of the
associations observed in the current study probably reflects non-genetic factors that
aggregate in the family environment. Nevertheless, the data provided herein would represent
a plausible estimate for the upper limit of genetic influence.
The sibling relative risk (λs) is an important measure of familial aggregation that is used as a
guide to estimate the feasibility of identifying genetic factors (42, 57). Ultimately the
feasibility of detecting a genetic effect depends on the genotypic relative risk and the
frequency of the disease associated allele, neither of which can be reliably estimated from h2
or λs (42). Simulation has suggested that λs>2.3 suggests but does not guarantee that a
disease susceptibility gene locus can be mapped if there are gene-gene or gene-environment
interactions (42). As context, λs for schizophrenia and type 1 diabetes are approximately 9
and 60, respectively (57), suggesting that the genetic dissection of these traits is more likely
to be tractable. For the phenotypes studied in siblings with hepatitis C infection, λs is
relatively small (ranging between 1.6 and 2.1). This suggests that genes with high genotypic
relative risk may not exist and that detecting polymorphisms that affect viral clearance and
disease progression will require large sample size or analysis, ideally taking into account
gene-environment interactions. This information is extremely important when assessing the
feasibility of gene mapping studies in this population and serves as a cautionary note for
future investigations.
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Table 1
Demographic characteristics of all hemophiliacs and hemophilic siblings with hepatitis C infection
Characteristic Total Hemophilic Population (n=3993) Subset of Siblings (n=514) p value
Hemophilia type
 A 3112 (78.3%) 426 (82.9%)
 B 617 (15.5%) 66 (12.9%) p=0.04
 Other 247 (6.2%) 22 (4.2%)
Severity of hemophilia
 Mild 706 (17.7%) 67 (13%)
 Moderate 607 (15.3%) 72 (14%) p=0.01
 Severe 1663 (67.0%) 375 (73%)
Age at HCV infection
 Median 7.5 years 7.5 years
HIV status
 HIV + 1815 (45.5%) 278 (54.1%) p=0.002
 HIV - 2177 (54.5%) 236 (45.9%)
HBsAg + 234 (6.6%) 35 (7.4%) ns
Alcohol usage (weekly)
 None 1761 (51.2%) 239 (52.5%) ns
 < 8 drink/week 1302 (37.8%) 160 (35.1%)
 8-14 drinks/week 235 (6.8%) 34 (7.5%)
 > 14 drinks/week 144 (4.2%) 22 (4.9%)
HCV RNA status
 HCV RNA + 2512 (76.6%) 357 (77.1) ns
 HCV RNA − (spontaneous) 562 (16.4%) 72 (15.6%)
 HCV RNA − (treated) 204 (6.2%) 34 (7.3%)
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Table 2
Expected and observed concordance rates for viral clearance and advanced liver disease within hemophilic
sibships.
Expected Observed in sib pairs p value
Spontaneous HCV clearance (Total population) 2.7% 4.0% p=0.07
Spontaneous HCV clearance (HIV-negative) 4.3% 8.8% p=0.04
Treatment-related HCV clearance 13.3% 31.3% p=ns
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Table 3
Heritability and sibling relative risk for spontaneous and treatment-induced viral clearance and for the
development of advanced liver disease in hemophiliacs with hepatitis C infection.
Heritability (h2) P value Sibling Relative Risk (λs)
Spontaneous viral clearance 0.25 ± 0.14 P=0.04 1.6
Treatment-induced viral clearance 0.43 ± 0.42 p=0.10 1.7
Advanced liver disease 0.29 ± 0.13 P=0.02 2.1
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Table 4
Clinical and laboratory features of advanced liver disease.
Characteristic Total Hemophilic Population (n=2238) Subset of Hemophilia Siblings (n=250) p value
Encephalopathy 38 (1.7%) 7 (2.8%) ns
Ascites 128 (5.7%) 19 (7.6%) ns
Esophageal varices 68 (3.0%) 4 (1.6%) ns
Bridging fibrosis or cirrhosis on biopsy 31 (24%) 3 (23%) ns
Liver cancer 9 0 ns
Liver death 105 (4.7%) 13 (5.2%) ns
Hypoalbuminemia 103 (7.9%) 16 (10.4%) ns
Thrombocytopenia 262 (11.7%) 28 (11.2%) ns
Bilirubin > 85 (5.7%) 12 (7.1%) ns
Prolonged prothrombin time 118 (11%) 18 (13%) ns
Cirrhosis 57 (2.6%) 5 (2.0%) ns
Platelets < 100,000 c/mm3 146 (6.5%) 13 (5.2%) ns
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